Investigational drug · Phase 2
MN-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "MN-001"
First trial start
2022
Aug 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MN-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes Mellitus, Type 2
- Hypertriglyceridemia
- Non-Alcoholic Fatty Liver Disease
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MN-001" as an intervention, largest first.
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisPivotal-lookingCompleted
MediciNovaIndustry
NCT00295854 · 296 participants · Start May 2005 · Primary completion Oct 2006
Drug: MN-001 BID; MN-001 and 1 more · For: Interstitial Cystitis
Sites: Birmingham, Alabama; Glendora, California; Long Beach, California · 28 sites in all
- MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaActive, not recruiting
MediciNovaIndustry
NCT05464784 · 40 participants (planned) · Start Aug 22, 2022 · Primary completion Dec 31, 2026
Drug: MN-001; MN-001 placebo · For: Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease
Sites: Las Vegas, Nevada; Edinburg, Texas
MediciNovaIndustry
NCT02681055 · 19 participants · Start Mar 2016 · Primary completion May 30, 2018
Drug: MN-001 · For: Non-alcoholic Steatohepatitis; Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease and 1 more
Sites: Coronado, California; La Jolla, California; Seattle, Washington
MediciNovaIndustry
NCT02503657 · 15 participants · Start Mar 9, 2016 · Primary completion Dec 7, 2020
Drug: MN-001; Placebo · For: Idiopathic Pulmonary Fibrosis; IPF
Sites: Hershey, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis.
Qi H, Ogura M, Matsuda K, et al. · J Atheroscler Thromb 2026
- Single molecule magnetoresistance with combined antiferromagnetic and ferromagnetic electrodes.
Bagrets A, Schmaus S, Jaafar A, et al. · Nano Lett 2012
- MN 001: KCA 757, KCA-757, MN-001.
· Drugs R D 2007
- MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model.
Rajasekaran M, Locke KW, Parsons CL · BJU Int 2006
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2005
- Observation of spin-polarized surface states on ultrathin bct Mn(001) films by spin-polarized scanning tunneling spectroscopy.
Yamada TK, Bischoff MM, Heijnen GM, et al. · Phys Rev Lett 2003
Also in development for Diabetes Mellitus, Type 2
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.